Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence.
暂无分享,去创建一个
S. Jones | B. Forbes | R. Telford | F. Buttini | S A Jones | C I Grainger | M Saunders | F Buttini | R Telford | L L Merolla | G P Martin | B Forbes | G. Martin | M. Saunders | L. Merolla | C. I. Grainger
[1] Zengri J. Wang,et al. Bioequivalence of Press- and- Breathe and Breath-Actuated Inhalers of Beclomethasone Dipropionate Extrafine Aerosol , 2002 .
[2] Peter Meredith,et al. Bioequivalence and other unresolved issues in generic drug substitution. , 2003, Clinical therapeutics.
[3] S. Newman,et al. Improved targeting of beclomethasone diproprionate (250 μg metered dose inhaler) to the lungs of asthmatics with the Spacehaler , 1999 .
[4] L. Harrison,et al. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. , 1998, Respiratory medicine.
[5] R. Tiner,et al. Aerosol drug delivery: developments in device design and clinical use , 2011, The Lancet.
[6] A. Kirschbaum,et al. Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model , 2005, Respiratory research.
[7] R. B. Walker,et al. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[8] Hugh D C Smyth,et al. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. , 2003, Advanced drug delivery reviews.
[9] G. Colice,et al. Particle size of inhaled corticosteroids: does it matter? , 2009, The Journal of allergy and clinical immunology.
[10] Robert Combes,et al. In vitro models of inhalation toxicity and disease. The report of a FRAME workshop. , 2009, Alternatives to laboratory animals : ATLA.
[11] Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered-dose inhalers: potential advantages and disadvantages. , 1999, Chest.
[12] B. Rothen‐Rutishauser,et al. A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[13] B. Müller,et al. Metered-dose inhaler formulations with beclomethasone-17,21-dipropionate using the ozone friendly propellant R 134a. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[14] Ben Forbes,et al. Culture of Calu-3 Cells at the Air Interface Provides a Representative Model of the Airway Epithelial Barrier , 2006, Pharmaceutical Research.
[15] A. Hickey,et al. Development of a Size-dependent Aerosol Deposition Model Utilising Human Airway Epithelial Cells for Evaluating Aerosol Drug Delivery , 2004, Alternatives to laboratory animals : ATLA.
[16] E. Ormsby,et al. Metered-dose inhalers, I: Drug content and particle size distribution of beclomethasone dipropionate. , 1996, Journal of pharmaceutical and biomedical analysis.
[17] R. Pauwels,et al. Pharmacokinetic and Pharmacodynamic Properties of Inhaled Beclometasone Dipropionate Delivered Via Hydrofluoroalkane-Containing Devices , 2005, Clinical pharmacokinetics.
[18] B. Forbes,et al. In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate , 2001, AAPS PharmSciTech.
[19] Svetlana Lyapustina,et al. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[20] G. P. Martin,et al. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[21] N Lotan,et al. Large porous particles for pulmonary drug delivery. , 1997, Science.
[22] O. Usmani,et al. Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .
[23] G. P. Martin,et al. Integrated in vitro experimental modelling of inhaled drug delivery: deposition, dissolution and absorption , 2011 .
[24] A. Woodcock,et al. Modulite technology: pharmacodynamic and pharmacokinetic implications. , 2002, Respiratory medicine.
[25] C. Leach. Improved delivery of inhaled steroids to the large and small airways. , 1998, Respiratory medicine.
[26] C. Leach,et al. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers. , 2002, Chest.
[27] H. Ortega,et al. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing , 2009, Clinical therapeutics.